Cytosorbents (CTSO) Capital Expenditures Growth (1y) (2012 - 2026)
Powered by 
Analysis
Cytosorbents (CTSO) Capital Expenditures Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -1.00% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -27.50% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -0.20% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 10.38% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 24.20% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 35.70% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 5.88% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -9.99% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -6.52% |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | 106.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 106.54% |
| Mar 31, 2026 | -95.65% |
| Dec 31, 2025 | 56.52% |
| Sep 30, 2025 | -88.82% |
| Jun 30, 2025 | -1,301.64% |
| Mar 31, 2025 | 459.85% |
| Dec 31, 2024 | -27.75% |
| Sep 30, 2024 | 6.74% |
| Jun 30, 2024 | 108.50% |
| Mar 31, 2024 | -91.13% |
| Dec 31, 2023 | -55.26% |
| Sep 30, 2023 | -77.74% |
| Jun 30, 2023 | -106.76% |
| Mar 31, 2023 | -76.13% |
| Dec 31, 2022 | -86.07% |
| Sep 30, 2022 | -28.24% |
| Jun 30, 2022 | 292.92% |
| Mar 31, 2022 | 398.21% |
| Dec 31, 2021 | 845.91% |
| Sep 30, 2021 | 287.84% |